A hydrophobic site on the GLP-1 receptor extracellular domain orients the peptide ligand for signal transduction

Molecular Metabolism

Volumn 2, Issue 2, 2013, Pages 86-91

  Patterson, James T ^a,b   Li, Pengyun ^a   Day, Jonathan W ^a,c   Gelfanov, Vasily M ^a   DiMarchi, Richard D ^a  

^a INDIANA UNIVERSITY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Exendin 4; GLP 1; Glucagon; GPCR; Receptor activation

Indexed keywords

ALANINE; AMINO ACID; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUTAMINE; GLYCINE; LEUCINE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; EMBRYO; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 84877651455     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2013.01.003     Document Type: Article

References (33)

1. Elrick H., Stimmler L., Hlad C.J., Arai Y. Plasma insulin response to oral and intravenous glucose administration. Journal of Clinical Endocrinology and Metabolism 1964, 24:1076-1082.
2. Perley M.J., Kipnis D.M. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. Journal of Clinical Investigation 1967, 46:1954-1962.
3. Takhar S., Gyomorey S., Su R.C., Mathi S.K., Li X., Wheeler M.B. The third cytoplasmic domain of the GLP-1[7-36 amide] receptor is required for coupling to the adenylyl cyclase system. Endocrinology 1996, 137:2175-2178.
4. Drucker D.J. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002, 122:531-544.
5. Nogueiras R., Perez-Tilve D., Veyrat-Durebex C., Morgan D.A., Varela L., Haynes W.G., et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. Journal of Neuroscience 2009, 29:5916-5925.
6. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
7. Young A.A., Gedulin B.R., Bhavsar S., Bodkin N., Jodka C., Hansen B., et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999, 48:1026-1034.
8. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
9. Deacon C.F., Knudsen L.B., Madsen K., Wiberg F.C., Jacobsen O., Holst J.J. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998, 41:271-278.
10. Adelhorst K., Hedegaard B.B., Knudsen L.B., Kirk O. Structure-activity studies of glucagon-like peptide-1. Journal of Biological Chemistry 1994, 269:6275-6278.
11. Hareter A., Hoffmann E., Bode H.P., Goke B., Goke R. The positive charge of the imidazole side chain of histidine7 is crucial for GLP-1 action. Endocrine Journal 1997, 44:701-705.
12. Lopez de Maturana R., Donnelly D. The glucagon-like peptide-1 receptor binding site for the N-terminus of GLP-1 requires polarity at Asp198 rather than negative charge. FEBS Letters 2002, 530:244-248.
13. Andersen N.H., Brodsky Y., Neidigh J.W., Prickett K.S. Medium-dependence of the secondary structure of exendin-4 and glucagon-like-peptide-1. Bioorganic and Medicinal Chemistry 2002, 10:79-85.
14. Neidigh J.W., Fesinmeyer R.M., Prickett K.S., Andersen N.H. Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states. Biochemistry 2001, 40:13188-13200.
15. Day J.W., Ottaway N., Patterson J.T., Gelfanov V., Smiley D., Gidda J., et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nature Chemical Biology 2009, 5:749-757.
16. Miranda L.P., Winters K.A., Gegg C.V., Patel A., Aral J., Long J., et al. Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity. Journal of Medicinal Chemistry 2008, 51:2758-2765.
17. Murage E.N., Schroeder J.C., Beinborn M., Ahn J.M. Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1. Bioorganic and Medicinal Chemistry 2008, 16:10106-10112.
18. Patterson J.T., Day J.W., Gelfanov V.M., DiMarchi R.D. Functional association of the N-terminal residues with the central region in glucagon-related peptides. Journal of Peptide Science 2011, 17:659-666.
19. Runge S., Schimmer S., Oschmann J., Schiodt C.B., Knudsen S.M., Jeppesen C.B., et al. Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain. Biochemistry 2007, 46:5830-5840.
20. Lopez de Maturana R., Willshaw A., Kuntzsch A., Rudolph R., Donnelly D. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1. Journal of Biological Chemistry 2003, 278:10195-10200.
21. Runge S., Thogersen H., Madsen K., Lau J., Rudolph R. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. Journal of Biological Chemistry 2008, 283:11340-11347.
22. Underwood C.R., Garibay P., Knudsen L.B., Hastrup S., Peters G.H., Rudolph R., et al. Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. Journal of Biological Chemistry 2010, 285:723-730.
23. Al-Sabah S., Donnelly D. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors. British Journal of Pharmacology 2003, 140:339-346.
24. Knudsen L.B., Kiel D., Teng M., Behrens C., Bhumralkar D., Kodra J.T., et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:937-942.
25. Gespach C., Bataille D., Vauclin N., Moroder L., Wunsch E., Rosselin G. Secretin receptor activity in rat gastric glands. Binding studies, cAMP generation and pharmacology. Peptides 1986, 7(1):155-163.
26. Bourgault S., Vaudry D., Segalas-Milazzo I., Guilhaudis L., Couvineau A., Laburthe M., et al. Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor. Journal of Medicinal Chemistry 2009, 52:3308-3316.
27. Dong M., Le A., Te J.A., Pinon D.I., Bordner A.J., Miller L.J. Importance of each residue within secretin for receptor binding and biological activity. Biochemistry 2011, 50:2983-2993.
28. Patterson J.T., Ottaway N., Gelfanov V.M., Smiley D.L., Perez-Tilve D., Pfluger P.T., et al. A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1. ACS Chemical Biology 2011, 6:135-145.
29. Day J.W., Li P., Patterson J.T., Chabenne J., Chabenne M.D., Gelfanov V.M., et al. Charge inversion at position 68 of the glucagon and glucagon-like peptide-1 receptors supports selectivity in hormone action. Journal of Peptide Science 2011, 17:218-225.
30. Koth C.M., Murray J.M., Mukund S., Madjidi A., Minn A., Clarke H.J., et al. Molecular basis for negative regulation of the glucagon receptor. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:14393-14398.
31. Karnik S.S., Gogonea C., Patil S., Saad Y., Takezako T. Activation of G-protein-coupled receptors: a common molecular mechanism. Trends in Endocrinology and Metabolism 2003, 14:431-437.
32. Bergwitz C., Gardella T.J., Flannery M.R., Potts J.T., Kronenberg H.M., Goldring S.R., et al. Full activation of chimeric receptors by hybrids between parathyroid hormone and calcitonin. Evidence for a common pattern of ligand-receptor interaction. Journal of Biological Chemistry 1996, 271:26469-26472.
33. Runge S., Wulff B.S., Madsen K., Brauner-Osborne H., Knudsen L.B. Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity. British Journal of Pharmacology 2003, 138:787-794.